The Association Between Prebooster Vaccination Antibody Levels and the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 Infection

Noam Barda; Michal Canetti; Mayan Gilboa; Keren Asraf; Victoria Indenboim; Yael Weiss-Ottolenghi; Sharon Amit; Daniel Zubli; Ram Doolman; Ella Mendelson; Laurence S Freedman; Yitshak Kreiss; Yaniv Lustig; Gili Regev-Yochay

doi:10.1093/cid/ciac886

The Association Between Prebooster Vaccination Antibody Levels and the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 Infection

Clin Infect Dis. 2023 Apr 3;76(7):1315-1317. doi: 10.1093/cid/ciac886.

Authors

Noam Barda^{1

2

3

4}, Michal Canetti^{4

5

6}, Mayan Gilboa^{4

5

6}, Keren Asraf^{6

7}, Victoria Indenboim^{6

8}, Yael Weiss-Ottolenghi^{4

5

6}, Sharon Amit^{6

9}, Daniel Zubli^{4

5}, Ram Doolman^{6

8}, Ella Mendelson^{6

7}, Laurence S Freedman¹⁰, Yitshak Kreiss^{6

11}, Yaniv Lustig^{6

8}, Gili Regev-Yochay^{4

5

6}

Affiliations

¹ ARC Innovation Center, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel.
² Software and Information Systems Engineering, Ben-Gurion University of the Negev, Be'er Sheva, Israel.
³ Epidemiology, Biostatistics and Community Health Sciences, Ben-Gurion University of the Negev, Be'er Sheva, Israel.
⁴ Sheba Pandemic Preparedness Research Institute, Sheba Medical Center, Ramat-Gan, Israel.
⁵ Infection Prevention and Control Unit, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel.
⁶ Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
⁷ Dworman Automated-Mega Laboratory, Sheba Medical Center, Ramat-Gan, Israel.
⁸ Central Virology Laboratory, Public Health Services, Ministry of Health, Ramat-Gan, Israel.
⁹ Clinical Microbiology, Sheba Medical Center, Ramat-Gan, Israel.
¹⁰ Biostatistics and Biomathematics Unit, Gertner Institute of Epidemiology and Health Policy Research, Ramat-Gan, Israel.
¹¹ General Management, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel.

PMID: 36366729
DOI: 10.1093/cid/ciac886

Abstract

The correlation between anti-severe acute respiratory syndrome coronavirus 2 antibody levels and infection was reported. Here, we estimated the role of pre-fourth dose levels using data from 1098 healthcare workers. The risk of infection was reduced by 46% (95% confidence interval, 29%-59%) for each 10-fold increase in prebooster levels. Prebooster antibody levels could be used to optimally time boosters.

Keywords: IgG levels; SARS-CoV-2; boosters; infection risk; mRNA vaccines.

MeSH terms

Antibodies, Viral
COVID-19*
Health Personnel
Humans
Immunization, Secondary
Vaccination

Substances

Antibodies, Viral